https://www.linkedin.com/posts/wolfgangliedtke_aaic2025-alzheimers-autophagy-ugcPost-7357622079447257088-D3Uc?utm_medium=ios_app&rcm=ACoAAEeipBwBAWQhCS6XQWsJBTqNpzO3TJVoHkA&utm_source=screenshot_social_share&utm_campaign=copy_link Wolfgang Liedtke in • Following Senior Advisor Clinical Neuroscience 2w • Edited • G AAIC2025 Alzheimer meeting in the rearview mirror - Anavex with blarcamesine update AAIC2025 came to an end this week. A dynamic meeting where a global crowd came together in Toronto. We are past the era of diligent phenotyping while empathetically watching Alzheimer patients go down. We heard about long-term extension studies of disease modifying treatments, amongst them Dr Marwan Sabbagh's presentation "Ending on a high note" on very encouraging results of ATTENTION-AD, the open-label extension study of AD-004, which reported overall safe and effective treatment in a registrational clinical trial of blarcamesine, neural autophagy enhancer by activation of Sigmal-receptor, an intracellular chaperone whose client proteins contain key members of the autophagy machinery. https:///nkd.in/e9xTVXFP https://lnkd.in/ehFtm2D9 https://Inkd.in/e2_EviW7 Since in AD-004 the inflection point between blarcamesine-treated and placebo-treated groups was at 9 months, with 12 months trial duration, the open label extension was important. Results, read out for up to 4 years were impressively affirmative, as also presented in May by Dr Timo Grimmer of Munich at the AD/PD2025 meeting in Vienna. https://Inkd.in/e_V-ikhf https://Inkd.in/eXdYUp87 AD-004 results are also interesting in terms of shedding light on genetic predisposition of treated patients, a new direction in disease modifying treatments of Alzheimer's disease toward personalized medicine, as also emphasized in his presentation by Dr Sabbagh, and also presented by Dr Sabbagh and Dr Audrey Gabelle.
Genetic variation in the SIGMAR1 gene, which encodes the target for blarcamesine, can be associated with an attenuated treatment effect. The wildtype allele of SIGMAR1 is associated with a more effective response, and is present in 70% of the population. This represents a human pharmacogenetic validation of target engagement of blarcamesine in its cognition-preserving effects. Those were some of the exciting news from AAIC2025 - thanks to everybody who stopped by for a refreshing chat at the Anavex booth.
Market Data 
Markets 
AI
